Fagron NV (EBR:FAGR)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 1.73B |
| Revenue (ttm) | 952.17M |
| Net Income (ttm) | 91.02M |
| Shares Out | 73.35M |
| EPS (ttm) | 1.24 |
| PE Ratio | 19.07 |
| Forward PE | 16.02 |
| Dividend | 0.40 (1.69%) |
| Ex-Dividend Date | May 19, 2025 |
| Volume | 71,593 |
| Average Volume | 142,045 |
| Open | 23.70 |
| Previous Close | 23.65 |
| Day's Range | 23.55 - 23.80 |
| 52-Week Range | 19.24 - 24.50 |
| Beta | 0.33 |
| RSI | 63.68 |
| Earnings Date | Jul 30, 2026 |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for av... [Read more]
Full Company ProfileFinancial Performance
In 2025, Fagron NV's revenue was 952.17 million, an increase of 9.20% compared to the previous year's 871.96 million. Earnings were 91.02 million, an increase of 12.99%.
Financial StatementsNews
Pete Pharma and Fagron Enter Strategic Distribution Partnership to Expand Access to Pharmaceutical 3D Printing Across North America
PHOENIX--(BUSINESS WIRE)--Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D pharmaceutical printing, delivery systems, and sca...
Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its sharehold...
Fagron NV Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 10.3% to €263 million, driven by LatAm and M&A, with EBITDA margin guidance at 20%. Integration of recent acquisitions is on track, and the outlook remains positive with mid to high single-digit organic growth expected.
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the le...
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of th...
Full Year 2025 Fagron NV Earnings Call Transcript
Full Year 2025 Fagron NV Earnings Call Transcript
Fagron NV Earnings Call Transcript: H2 2025
Revenue grew 9.2% to €952 million in 2025, with strong organic growth and margin expansion across all regions. Twelve acquisitions were announced, and integration is underway, while 2026 guidance calls for continued mid- to high single-digit growth and slight profitability improvement.
Pharma 5.0 delivers personalized treatment using AI, says Fagron CEO
Rafael Padilla, CEO of pharmaceuticals company, Fagron, discusses healthcare innovation, obesity drug safety, and the company's growth strategy amid global pricing pressures.
Fagron Announces Acquisitions Of Amara And Magilab
(RTTNews) - Fagron (FAGR.BR) announced acquisitions of a book of business from Amara, and Magilab. Amara is a player in the compounding sector, operating raw materials in Poland. Magilab is a speciali...
Half Year 2025 Fagron NV Earnings Call Transcript
Half Year 2025 Fagron NV Earnings Call Transcript
Fagron NV Earnings Call Transcript: Q3 2025
Normalized organic growth reached 8.5% in Q3, with full-year revenue guidance reaffirmed at EUR 930–950 million and profitability set to improve. Eight acquisitions and major capacity expansions support global growth, while EMEA and North America delivered strong segment results.
Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confi...
Fagron NV Earnings Call Transcript: H1 2025
H1 2025 saw 11.3% organic revenue growth, margin expansion to 20%, and strong performance across all regions, led by North America and LATAM. Four acquisitions expanded the global footprint, and guidance remains for mid to high single-digit organic growth and improved profitability.
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the ...
Fagron NV Transcript: CMD 2025
Management outlined a strategy for high single- to low double-digit organic growth through 2030, driven by operational excellence, innovation, and disciplined M&A. Financial guidance includes a margin step-up to 21% by 2027, strong cash conversion, and targeted expansion in key regions. Quality, capacity investments, and a refined brand strategy underpin the growth plan.
Record first-quarter revenue of €239 million, reflecting 14% topline growth
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron...
Fagron NV Earnings Call Transcript: H2 2024
Revenue grew 16.8% year-on-year to EUR 872 million, with margin up to 20% and strong cash flow conversion. North America led growth, driven by compounding services and GLP-1 drug shortages, while EMEA and LatAm showed resilience. Six acquisitions support ongoing market consolidation and portfolio expansion.
Fagron NV Earnings Call Transcript: Q3 2024
Nine-month organic revenue grew 12.6% at CER, with all regions contributing and three acquisitions announced. Full-year revenue guidance is reaffirmed at EUR 850–870 million, with profitability set to improve year-on-year despite FX headwinds and ongoing integration of recent deals.
Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...
Fagron NV Earnings Call Transcript: H1 2024
Strong H1 2024 results with 12.8% organic growth at CER and revenue of EUR 429 million, led by North America and Compounding Services. Upgraded full-year guidance to EUR 850–870 million, with margin improvement and major investments in capacity expansion in the U.S. and Netherlands.
Fagron NV Earnings Call Transcript: Q1 2024
Record revenue of €209 million in first quarter reflecting 15% topline growth
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagr...
Fagron NV Earnings Call Transcript: H2 2023
Fagron NV Earnings Call Transcript: Q3 2023
Continued strong third quarter performance with 11% topline growth to €191 million
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 milli...